These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

810 related items for PubMed ID: 7564517

  • 21. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis.
    Beishuizen A, Verhoeven MA, van Wering ER, Hählen K, Hooijkaas H, van Dongen JJ.
    Blood; 1994 Apr 15; 83(8):2238-47. PubMed ID: 8161789
    [Abstract] [Full Text] [Related]

  • 22. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR.
    Lancet; 1998 Nov 28; 352(9142):1731-8. PubMed ID: 9848348
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E, Mazur J, Söderhäll S, Porwit-MacDonald A.
    Leukemia; 2003 Jan 28; 17(1):138-48. PubMed ID: 12529671
    [Abstract] [Full Text] [Related]

  • 26. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan.
    Imashuku S, Terui K, Matsuyama T, Asami K, Tsuchiya S, Ishii E, Kawa K, Kosaka Y, Eguchi H, Tsuchida M, Ikuta K, Kato S, Koizumi S, Okamura J, Morimoto A, Hibi S, Hamaoka K, multi-institutional collaborative study in Japan.
    Bone Marrow Transplant; 2003 Jun 28; 31(12):1127-35. PubMed ID: 12796792
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia.
    O'Reilly J, Meyer B, Baker D, Herrmann R, Cannell P, Davies J.
    Leukemia; 1995 Apr 28; 9(4):624-7. PubMed ID: 7723395
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
    van der Velden VH, Willemse MJ, van der Schoot CE, Hählen K, van Wering ER, van Dongen JJ.
    Leukemia; 2002 May 28; 16(5):928-36. PubMed ID: 11986956
    [Abstract] [Full Text] [Related]

  • 32. Pattern of T-cell receptor delta gene rearrangement by Southern blotting and polymerase chain reaction technique in Hong Kong Chinese patients with non-T-cell hematological malignancies.
    Chan DW, Liang R, Kwong YL.
    Hematol Oncol; 1996 Jun 28; 14(2):57-66. PubMed ID: 8876635
    [Abstract] [Full Text] [Related]

  • 33. Detection of minimal residual disease in peripheral blood prior to clinical relapse of childhood acute lymphoblastic leukaemia using PCR.
    Lal A, Kwan E, Haber M, Norris MD, Marshall GM.
    Mol Cell Probes; 2001 Apr 28; 15(2):99-103. PubMed ID: 11292328
    [Abstract] [Full Text] [Related]

  • 34. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group.
    Br J Haematol; 2009 Aug 28; 146(3):292-9. PubMed ID: 19500099
    [Abstract] [Full Text] [Related]

  • 35. Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.
    Taylor JJ, Rowe D, Kylefjord H, Chessells J, Katz F, Proctor SJ, Middleton PG.
    Leukemia; 1994 Jan 28; 8(1):60-6. PubMed ID: 8289500
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L, López O, Martino R, Brunet S, Bellido M, Rubiol E, Sierra J, Nomdedéu JF.
    Haematologica; 2000 Jul 28; 85(7):704-10. PubMed ID: 10897122
    [Abstract] [Full Text] [Related]

  • 39. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G.
    Leukemia; 2008 Dec 28; 22(12):2193-200. PubMed ID: 18754029
    [Abstract] [Full Text] [Related]

  • 40. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M.
    Leukemia; 2006 Feb 28; 20(2):254-63. PubMed ID: 16341043
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.